Inactive/Delisted stock
Qualigen Therapeutics Stock (NASDAQ:QLGN)
Previous Close
$1.83
52W Range
$1.61 - $10.50
50D Avg
$2.84
200D Avg
$3.53
Market Cap
$3.04M
Avg Vol (3M)
$850.87K
Beta
-0.17
Div Yield
-
QLGN Company Profile
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.